Keratoconus is a degenerative disorder causing a cornea to progressively thin and become conical in shape.
This can seriously distort vision and may lead to a corneal transplant.
IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea.
The Orphan Drug Act provides incentives for companies to develop products for rare diseases affecting fewer than 200,000 people in the United States.
Incentives may include tax credits related to clinical trial expenses, an exemption from the FDA user fee, FDA assistance in clinical trial design and potential market exclusivity for seven years following approval.
IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea. IVMED-80 biomechanically strengthens the cornea through the daily application of a non-invasive, proprietary eye-drop. It has been granted Orphan Drug Designation by the FDA and will begin clinical development early 2018.
iVeena Delivery Systems is a privately held biopharmaceutical company that develops ophthalmology products. iVeena utilises a proprietary intracapsular drug delivery platform to enhance a medication's ocular bioavailability to anterior and posterior eye segments.
The lead product delivers dexamethasone to treat post-cataract pain and inflammation as well as enable the prevention of retinal thickening associated with cataract extraction. The company was formed to commercialise technology from the Moran Eye Center at the University of Utah.
iVeena is structured to develop product candidates through clinical trials and then out-license to pharmaceutical marketing partners.
Currently, iVeena has completed a pilot clinical trial of its lead product (IVMED-10) and is preparing two additional products for clinical trials in Q1 2018 including keratoconus (IVMED-80) and prophylaxis of retinal thickening associated with cataract extraction (IVMED-20).
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007